Share on Facebook Share on Twitter Email
Answers.com

Bimatoprost

 
Drug Info: Bimatoprost
Home > Library > Health > Drug Info

Brand names: Lumigan™

Chemical formula:



Bimatoprost eye solution

What is bimatoprost eye solution?

BIMATOPROST (Lumigan®) helps to reduce pressure in the eye for patients with increased pressure or open-angle glaucoma. Generic bimatoprost eye solution is not yet available.

What should I tell my health care provider before I take this medicine?

They need to know if you have, or have had, any of these conditions:
• eye abrasion, infection, or inflammation
• wear contact lenses
• closed-angle glaucoma
• an unusual or allergic reaction to bimatoprost or other medicines, foods, dyes, or preservatives
• pregnant or trying to get pregnant
• breast-feeding

How should I use this medicine?

Contact lenses should be removed prior to using bimatoprost eye solution. Contact lenses may be reinserted 15 minutes following application of bimatoprost to the eye.

Bimatoprost eye solution is only for use in the eye. Do not take by mouth. Follow the directions on the prescription label. Wash hands before and after use. Tilt the head back slightly and pull down the lower lid with the index finger to form a pouch. Try not to touch the tip of the dropper to your eye or into the pouch. Squeeze the prescribed number of drops into the pouch and gently close the eyes for 1—2 minutes. Do not blink. Use your doses at regular intervals. Do not use you medicine more often than directed.

Contact your pediatrician or health care professional regarding the use of this medicine in children. Special care may be needed.

What if I miss a dose?

If you miss a dose, use it as soon as you can. If it is almost time for your next dose, use only that dose. Do not use double or extra doses.

What drug(s) may interact with bimatoprost eye solution?

No interactions with other medicines have been reported.

Do not use any other eye products without telling your prescriber or health care professional.

Tell your prescriber or health care professional about all other medicines you are taking, including non-prescription medicines, nutritional supplements, or herbal products. Also tell your prescriber or health care professional if you are a frequent user of drinks with caffeine or alcohol, if you smoke, or if you use illegal drugs. These may affect the way your medicine works. Check with your health care professional before stopping or starting any of your medicines.

What should I watch for while taking bimatoprost?

Visit your prescriber or health care professional for regular checks on your progress. Report any serious side effects promptly. Stop using bimatoprost if your eyes get inflamed, painful, or have a discharge, and see your prescriber or health care professional as soon as you can.

This medicine may cause your eye, eyelashes, and eyelids to change color. Tell your prescriber or health care professional if this occurs. If only one eye is being treated with bimatoprost, a difference may develop between the treated and untreated eye in eyelash length, darkness or thickness, and/or color changes of the eyelid skin or iris. These changes may be permanent.

If you wear contact lenses, be sure to remove them before placing drops in the eye. Certain chemicals in the solution can be absorbed by contact lenses. Contact lenses may be reinserted 15 minutes following application of bimatoprost to the eye.

Be careful not to touch the tip of the dispensing container onto the eye, or any other surface. Serious eye infections can result from contamination of eye solutions.

If you are using another eye preparation, there should be an interval of at least 5 minutes between use of bimatoprost and the other eye preparation.

Wear dark glasses if bimatoprost makes your eyes more sensitive to light.

What side effects may I notice from using bimatoprost eye solution?

Side effects that you should report to your prescriber or health care professional as soon as possible:
• any change in your vision
• inflamed or infected eyes or eyelids

Side effects that usually do not require medical attention (report to your prescriber or health care professional if they continue or are bothersome):
• burning, stinging, or discomfort immediately after using the solution
• changes in eye, eyelash, or eyelid color
• dry eyes
• increased flow of tears
• sensitivity of the eyes to light

Where can I keep my medicine?

Keep out of the reach of children in a container that small children cannot open.

Store the bottle at room temperature at 15—25 degrees C (59—77 degrees F). Throw away any unused medicine after the expiration date.

Last updated: 7/1/2002

Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.

Search unanswered questions...

Enter a question here...
Search: All sources Community Q&A Reference topics

Wikipedia: Bimatoprost
Top
Home > Library > Miscellaneous > Wikipedia
Bimatoprost
Systematic (IUPAC) name
7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide
Identifiers
CAS number 155206-00-1
ATC code S01EE03
PubChem 5311027
DrugBank APRD00826
ChemSpider 4470565
Chemical data
Formula C25H37NO4 
Mol. mass 415.566 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes Topical (eye drops)
 Yes check.svgY(what is this?)  (verify)

Bimatoprost (sold in the U.S., Canada and Europe by Allergan, under the trade name Lumigan) is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes.[1] It has also been used and prescribed off-label to lengthen eyelashes.[2] In December 2008, this use was approved by the U.S. Food and Drug Administration; the cosmetic formulation of bimatoprost is sold as Latisse (pronounced /ləˈtiːs/).[3] Recently, at least three case series have suggested that bimatoprost has the ability to reduce adipose (fat) tissue.

Contents

Cosmetic use

In patients using ophthalmic prostaglandins such as travoprost and latanoprost, as well as prostamides like bimatoprost, it has been anecdotally noted that they have grown long and lush eyelashes. Allergan has initiated clinical trials investigating the usage of Lumigan as a cosmetic drug.[4] On December 5, 2008, the FDA Dermatologic and Ophthalmic Drugs Advisory Committee voted to approve bimatoprost for the cosmetic use of darkening and lengthening eyelashes. The medical term for this is treatment of hypotrichosis, however, the FDA approval is for purely cosmetic purposes.[5]

Several cosmetics companies have released products based on prostaglandin analogs, as non-drug cosmetics.

  • Age Intervention Eyelash by Jan Marini Skin Research
  • RevitaLash by Athena Cosmetics Corp.
  • MD Lash Factor by PhotoMedex Inc.

These companies have been sued by Allergan for patent infringement.[4] The FDA has seized Age Intervention Eyelash as an "unapproved and misbranded drug" because Jan Marini Skin Research promoted it as something that increases eyelash growth[6] and because it is "adulterated" with bimatoprost.[7]

Fat-reducing properties

Reductions in orbital fat (ie, fat around the eye) have been observed in patients using bimatoprost as glaucoma therapy.[8] Of particular interest, the loss of orbital fat was unilateral in patients who used bimatoprost on only one eye.[9] The effect appears reversible upon cessation of bimatoprost use. The effect is likely to explain deepening of the lid sulcus described in a series of three patients on bimatoprost.[10] The mechanism for the apparent fat reduction remains unclear. However, bimatoprost is chemically analogous to prostaglandin F2 alpha (PGF2alpha), a compound which is known to reduce fat by inhibition of adipocyte differentiation and survival.[11]

Formulations

Lumigan is a 0.03% solution of bimatoprost, and contains benzalkonium chloride as a preservative. Contact lenses should therefore be removed before use, and replaced no less than 15 minutes later;[1] other eye drops or ointments should be given no less than 5 minutes before or after bimatoprost.[1] It is administered once daily.

Side effects

Possible side effects of this medication are:

  • May cause blurred vision.
  • May cause eyelid redness.
  • May permanently darken eyelashes.
  • May cause eye discomfort.
  • May eventually cause permanent darkening of the iris to brown.
  • May cause a temporary burning sensation during use.
  • May cause thickening of the eyelashes.

On November 19, 2007 the FDA issued a warning during the seizure of a bimatoprost-containing cosmetic.[12] The warning stated that "the extra dose of bimatoprost may decrease the prescription drug's effectiveness. Damage to the optic nerve may lead to decreased vision and possibly blindness."

References

  1. ^ a b c "Bimatoprost Ophthalmic". MedlinePlus. January 1, 2003. http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a602030.html. Retrieved 2007-11-19. 
  2. ^ "Drug That Lengthens Eyelashes Sets Off Flutter". The Wall Street Journal. 2007-11-19. http://online.wsj.com/article/SB119543055372597359.html. Retrieved 2007-11-19. 
  3. ^ Associated Press (December 26, 2008). "Allergan gets FDA approval for eyelash treatment". BusinessWeek. http://www.businessweek.com/ap/financialnews/D95AF4N81.htm.  Retrieved on December 26, 2008.
  4. ^ a b Wall Street Journal: Drug That Lengthens Eyelashes Sets Off Flutter RHONDA L. RUNDLE November 19, 2007; Page B1
  5. ^ The Pink Sheet: [1] LAUREN SMITH December 15th 2008; Volume 70, Number 050,Page
  6. ^ MSNBC: FDA Seizes $2 Million Of Potentially Harmful SJ Eye Product KNTV-TV 2:44 p.m. ET, Sat., Nov. 17, 2007
  7. ^ Reuters: U.S. seizes discontinued eyelash product Jim Wolf Fri Nov 16, 2007 11:48pm EST
  8. ^ Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D (May 2008). "Orbitale Fettgewebsatrophie bei lokaler Bimatoprost-Therapie - Kann Bimatoprost einen Enophthalmus verursachen? [Orbital fat atrophy in glaucoma patients treated with topical bimatoprost--can bimatoprost cause enophthalmos?]" (in German). Klinische Monatsblätter Für Augenheilkunde 225 (5): 443–5. doi:10.1055/s-2008-1027362. PMID 18454393. 
  9. ^ Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL (2008). "Periorbital changes associated with topical bimatoprost". Ophthalmic Plastic and Reconstructive Surgery 24 (4): 302–7. doi:10.1097/IOP.0b013e31817d81df. PMID 18645437. 
  10. ^ Peplinski LS, Albiani Smith K (August 2004). "Deepening of lid sulcus from topical bimatoprost therapy". Optometry and Vision Science 81 (8): 574–7. doi:10.1097/01.opx.0000141791.16683.4a. PMID 15300114. 
  11. ^ Serrero G, Lepak NM (April 1997). "Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium". Biochemical and Biophysical Research Communications 233 (1): 200–2. doi:10.1006/bbrc.1997.6433. PMID 9144422. 
  12. ^ U.S. Food and Drug Administration (November 19, 2007). "Potentially Harmful "Cosmetic" Eye Product Seized". Press release. http://www.fda.gov/consumer/updates/cosmeticeye111907.html. Retrieved 2007-12-05. 

Citations

  • Chen M, Cheng C, Chen Y, Chou C, Hsu W (2006). "Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma.". J Ocul Pharmacol Ther 22 (3): 188–93. doi:10.1089/jop.2006.22.188. PMID 16808680. 
  • Kruse P, Rieck P, Sherif Z, Liekfeld A (2006). "Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?". Klin Monatsbl Augenheilkd 223 (6): 534–7. doi:10.1055/s-2005-858992. PMID 16804825. 
  • Steinhäuser S (2006). "Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.". Optometry 77 (4): 177–9. doi:10.1016/j.optm.2006.02.001. PMID 16567279. 
  • Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D (2008). "[Orbital fat atrophy in glaucoma patients treated with topical bimatoprost--can bimatoprost cause enophthalmos?]". Klin Monatsbl Augenheilkd 225 (5): 443–5. doi:10.1055/s-2008-1027362. PMID 18454393. 
  • Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL (2008). "Periorbital changes associated with topical bimatoprost.". Ophthal Plast Reconstr Surg 24 (4): 302–7. doi:10.1097/IOP.0b013e31817d81df. PMID 18645437. 
  • Peplinski LS, Albiani Smith K (2004). "Deepening of lid sulcus from topical bimatoprost therapy.". Optom Vis Sci 81 (8): 574–7. doi:10.1097/01.opx.0000141791.16683.4a. PMID 15300114. 

External links


v • d • e
Ophthalmologicals: antiglaucoma preparations and miotics (S01E)
Sympathomimetics
Parasympathomimetics
muscarinic/nicotinic
Carbonic anhydrase inhibitors/
(sulfonamides)
Beta blocking agents
Prostaglandin analogues (F2α)
Bimatoprost • Latanoprost • Tafluprost • Travoprost • Unoprostone
Other agents
v • d • e
Autacoids, unsaturated fatty acids: Eicosanoids
Precursor
Prostanoids
Precursor
Active
D/J
E/F
I
A2 · B2
Leukotrienes (LT)
Precursor
Initial
A4 · B4
C4 · D4 · E4
Nonclassic
By function

bronchoconstriction (PGF2α, TXA2, LTC4, LTD4, LTE4)

vasoconstriction (PGF2α, TXA2, TXB2) · vasodilation (PGE2, PGI2, LTC4, LTD4, LTE4)

platelets: induce (TXA2) inhibit (PGD2, PGI2) · leukocytes: induce (TXA2, LTB4) inhibit (PGD2, PGE2)

labor stimulation: (PGE2 (Dinoprostone), PGF2α (Dinoprost))
see also enzymes

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)

 
 

 

Copyrights:

Drug Info. Gold Standard. Copyright © 2008 by Gold Standard. All rights reserved.  Read more
Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "Bimatoprost".  Read more